* ANACONDA PHARMA *
2003 - IDF
Paris
www.anacondapharma.com Discovery, Drugs
Key words: Protein interactions, Condyloma, Anti-viral
Mission: to develop a proprietary platform for the discovery of small molecules that disrupt protein:protein interactions, as a distinct unexploited class of pharmaceutical targets, due to the difficulty of recognizing drugable hot-spots on the surface of interacting proteins
Clients: Prescribers
contact@anacondapharma.com
Age: 8 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Spin-off |
Managing Dir.-CEO: Blumenfeld (Marta) [born 1955, Ph.D. Biochemistry, ex-Genset]
Sc.Dir.-CSO:
Med.Dir.: Compère (Delphine) [Ph.D. organic chemistry, ex-Pfizer, Cerep]
Fin.Dir.-CFO: Bali (Ismahane) [Ms accounting, ex-Audit and Diagnostic]
BusDev:
Financers (Hist.): privately owned (private investors) | Turnover (M€) : 0.015 (2006)
Total funding (M€) : 3.6
Last funding (M€) : 2.6
Focus : Cancers
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2009 .04 | Financing (no interest loan) : 0.5 M€, by OSEO (already a similar funfing in 2004) | DEBT | [5 years] |
| 2008 .05 | Company move from Paris Pasteur Biotop incubator to Paris Biopark with new R&D facilities | ORGL | [4 years] |
| 2007 .01 | Round-financing : 2.6 M€, by private investors | RFIN | [3 years] |
| 2006 .10 | Financing : leader company in the CristaLead Program, with a minimum of € 1 Million grant | RFIN | [3 years] |
| 2003 .10 | Company founded by Dr Moshe Yaniv and Dr Françoise Thierry (both from Institut Pasteur), Dr Michael Botchan (Berkeley), and Marta Blumenfeld and Jean-Michel Gauthier, as a spin-off from Institut Pasteur | ORGF | [0 year] | Actualisation / Updating: 3-May-2011 |
|
